leadf
logo-loader
viewIXICO PLC

IXICO joins neuroimaging consortium focused on Friedreich’s Ataxia

FA is a rare genetic disease that causes difficulty walking, a loss of sensation in the arms and legs and impaired speech

IXICO PLC - IXICO joins neuroimaging consortium focused on Friedreich’s Ataxia

IXICO PLC (LON:IXI) said it has entered a five year collaboration with the Friedreich's Ataxia Research Alliance (FARA) to become a member of the TRACK-FA neuroimaging consortium, focused on exploring novel imaging markers for Friedreich’s Ataxia (FA).

FA is a rare genetic disease that causes difficulty walking, a loss of sensation in the arms and legs and impaired speech. The disease can also damage parts of the brain and spinal cord and affect the heart.

READ: IXICO to supply its imaging expertise to leading Alzheimer’s trial

IXICO, an AIM-listed neuroscience data analytics specialist, said it will support the consortium to implement novel analysis algorithms with the aim of providing a trial-ready imaging solution for FA clinical trials.

The company added that it will be an industry member and stakeholder in the consortium and will work alongside academic partners with expertise in neuroimaging and conducting clinical research in FA including Monash University in Australia), the University of Minnesota and Aachen University in Germany.

IXICO said while the contract will not have a significant impact of management expectations for its performance this year, it will contribute to its “already strong year-end order book”.

"This new consortium will help to accelerate the quest for new treatments for Friedreich's Ataxia by bringing together some of the leading researchers in the field from both academia and industry with the specific goal of developing new tools to better understand and characterise this debilitating disease”, IXICO’s senior vice president for science and innovation Robin Wolz said in a statement.

“IXICO will bring its expertise in neuroimaging and AI to support the development and validation of new biomarkers which in turn will help to identify the most promising treatments and bring these to patients sooner", Wolz added.

Quick facts: IXICO PLC

Price: 97 GBX

AIM:IXI
Market: AIM
Market Cap: £45.68 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of IXICO PLC named herein, including the promotion by the Company of IXICO PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

IXICO revenues' rise for fourth consecutive year, up by 26%

IXICO PLC's (LON:IXI) Giulio Cerroni talks to Proactive London about his artificial intelligence-driven data analytics company. Cerroni explains the latest set of results, which show revenue rose by 26% to £9.5m, up from £7.6m the year before. He also highlights the order book which grew...

2 days, 12 hours ago

2 min read